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Abstract
A pro-thrombotic milieu and a higher risk of thrombotic events were observed in patients with CoronaVirus disease-19 
(COVID-19). Accordingly, recent data suggested a beneficial role of low molecular weight heparin (LMWH), but the optimal 
dosage of this treatment is unknown. We evaluated the association between prophylactic vs. intermediate-to-fully antico-
agulant doses of enoxaparin and in-hospital adverse events in patients with COVID-19. We retrospectively included 436 
consecutive patients admitted in three Italian hospitals. Outcome according to the use of prophylactic (4000 IU) vs. higher 
(> 4000 IU) daily dosage of enoxaparin was evaluated. The primary end-point was in-hospital death. Secondary outcome 
measures were in-hospital cardiovascular death, venous thromboembolism, new-onset acute respiratory distress syndrome 
(ARDS) and mechanical ventilation. A total of 287 patients (65.8%) were treated with the prophylactic enoxaparin regimen 
and 149 (34.2%) with a higher dosing regimen. The use of prophylactic enoxaparin dose was associated with a similar inci-
dence of all-cause mortality (25.4% vs. 26.9% with the higher dose; OR at multivariable analysis, including the propensity 
score: 0.847, 95% CI 0.400–0.1.792; p = 0.664). In the prophylactic dose group, a significantly lower incidence of cardio-
vascular death (OR 0.165), venous thromboembolism (OR 0.067), new-onset ARDS (OR 0.454) and mechanical intubation 
(OR 0.150) was observed. In patients hospitalized for COVID-19, the use of a prophylactic dosage of enoxaparin appears 
to be associated with similar in-hospital overall mortality compared to higher doses. These findings require confirmation in 
a randomized, controlled study.
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Highlights
• Thrombosis and inflammation have an interacting and 
circular relationship in COVID-19.
• In patients with COVID-19, a hypercoagulable state justi-
fies the use of heparin as prophylaxis for future throm-
botic events.
• A prophylactic dosage of enoxaparin seems to be asso-
ciated with similar in-hospital mortality compared to 
higher doses
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Introduction
Coronavirus Disease-2019 (COVID-19), caused by 
Severe Acute Respiratory Syndrome CoronaVirus-2 
(SARS-CoV-2) infection, was first described in China in 
December 2019; since then, it has rapidly become a global 
pandemic [1]. Patients hospitalized for COVID-19 usu-
ally present a respiratory syndrome, but several reports 
have described an increased occurrence of macrovascular 
thrombotic complications, with attendant higher mortal-
ity [2, 3]. Indeed, autoptic data also indicated a diffuse 
microvascular thrombosis in the lungs of patients who died 
for COVID-19 [4–6]. Thus, based on such evidence and 
on real-world data suggesting a clinical benefit of antico-
agulant therapy [7–10], patients hospitalized for COVID-
19 commonly receive early treatment with low molecular 
weight heparin (LMWH). Although the World Health 
Organization supported a strategy with LMWH at pro-
phylactic dosage (4000 IU daily) [11], in patients admitted 
for COVID-19 it is common practice to use intermediate-
to-therapeutic (i.e., fully anticoagulant) doses of LMWH. 
This is in agreement with recent reports showing a pro-
thrombotic milieu in such patients [2, 12]. Thus, due to 
the lack of specific comparison data, the optimal dosage 
of LMWH in this setting is unknown and debated. In this 
retrospective, multicenter study, we specifically investi-
gated the in-hospital outcome with prophylactic vs. higher 
dosage of LMWH in patients hospitalized for COVID-19.
Methods
Study population
Consecutive patients aged ≥ 18 years and admitted for 
COVID-19 from February 20 to May 12, 2020, in three 
Italian Hospitals (Maggiore della Carità Hospital of 
Novara; Sant’Andrea Hospital of Vercelli; Policlinico 
Santissima Annunziata of Chieti) were included. All 
patients had a nasopharyngeal swab tested positive for 
molecular detection of SARS-CoV-2 RNA by reverse-
transcriptase–polymerase-chain-reaction assay.
A total of 637 patients with COVID-19 were admitted 
during the study period. For the purpose of the study, we 
considered those patients receiving LMWH at any time 
during the in-hospital stay. Two-hundred-one patients 
were excluded from the analysis: 157 patients because 
they did not receive LMWH due to clinical decision of the 
treating physician; 23 patients due to lack of information 
on the LMWH dose; 4 patients who received thrombo-
prophylaxis with fondaparinux; 17 patients treated with 
oral anticoagulant agents. Thus, a total of 436 patients 
represent the study population. The flow diagram indicat-
ing how the final number of included patients was obtained 
is reported in Fig. 1 of the Online Appendix. The choice 
of dosing regimen of LMWH and timing of LMWH initia-
tion was left to the physician’s discretion; however, as per 
internal in-hospital protocols, patients deemed suitable for 
pharmacological prevention of thrombotic events generally 
received subcutaneous LMWH early after the admission, 
and LMWH was enoxaparin in all cases. No antiplatelet 
therapy or unfractionated heparin were given for thrombo-
prophylaxis; unfractionated heparin was utilized only in 
patients with thrombotic complications during hospitaliza-
tion. In the analysis, no patient had received both LMWH 
doses; switching from prophylactic to higher enoxaparin 
doses was performed only in the case of in-hospital throm-
botic complication. Patients were included regardless of 
clinical features at presentation and in-hospital therapies 
for COVID-19. The Institutional Review Board approved 
the study protocol (IRB code CE 97/20), which was con-
ducted in strict accordance with the Declaration of Hel-
sinki principles.
Data collection
We identified patients hospitalized for COVID-19 from 
hospital administrative data. An electronic case report form 
was generated using the Research Electronic Data Capture 
software (REDCap, Vanderbilt University), where indi-
vidual data obtained after the revision of clinical records 
were entered. The data entry was retrospectively performed 
by investigators involved in the patient’s management. A 
unique pseudonymized code was assigned to each patient. 
Individual data included patients’ demographic details, 
comorbidities, vital signs, laboratory test results, medica-
tions and in-hospital events.
Investigational regimens exposure and study 
end‑points
Patients were divided according to the received enoxapa-
rin dose: prophylactic (4000 IU daily) vs. higher dosage 
(> 4000 IU daily). The primary end-point was the incidence 
of all-cause death during in-hospital stay in the two groups 
(prophylactic vs. higher dosing regimen).
The following in-hospital secondary end-points were 
considered:
– Cardiovascular mortality, defined as death resulting from 
an acute myocardial infarction, heart failure, stroke, pul-
monary embolism, or other cardiovascular causes [13].
– Venous thromboembolism, including pulmonary embo-
lism or deep venous thrombosis
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– New-onset severe acute respiratory distress syndrome 
(ARDS), defined according to the Berlin definition, as an 
acute (within a week), diffuse, inflammatory lung injury, 
not fully explained by cardiac failure or fluid overload, 
leading to increased pulmonary vascular permeability 
and loss of aerated lung tissue acute, with bilateral lung 
opacities consistent with pulmonary edema and ratio of 
the partial pressure of arterial oxygen to the fraction of 
inspired oxygen  (PaO2/FiO2) < 100 mmHg [14].
– Need for mechanical ventilation. Criteria for mechanical 
ventilation were: cardiac or respiratory arrest; inability 
to protect the airway; coma or psychomotor agitation; 
unmanageable secretions or uncontrolled vomiting; life-
threatening arrhythmias or electrocardiographic signs of 
ischemia; hemodynamic instability, defined as systolic 
arterial pressure less than 90 mmHg despite adequate 
filling or use of vasoactive agents; intolerance to all inter-
faces; dyspnea during noninvasive continuous positive 
airway pressure, a respiratory rate more than 30 breaths/
min; peripheral oxygen saturation below 92% during 
noninvasive continuous positive airway pressure; acido-
sis with a pH < 7.35.
– Major bleeding and clinically relevant non-major bleed-
ing, according to the International Society of Thrombosis 
and Haemostasis (ISTH) definition [15]. This analysis 
was performed on a subgroup of 86 consecutive patients 
whose bleeding complications were systematically col-
lected and validated.
All outcome events (both primary and secondary) were 
counted if they occurred after the admission and after the 
initiation of LMWH treatment. Patients without adverse 
events who were still hospitalized at the time of the analysis 
were not included in the analysis. The length of stay was 
reported as days from admission to discharge.
Statistical analysis
Continuous data are reported as mean ± standard deviation 
if normally distributed, or as median and interquartile range 
if not normally distributed, and were compared by Student 
t-test or Mann–Whitney U test, as appropriate. Categorical 
variables are indicated as number (percentage), and propor-
tions were compared by chi-squared test. Frequencies were 
calculated to examine the associations between LMWH 
doses and outcome.
Logistic regression models were used to estimate the 
independent association between LMWH dosing regimens 
and study end-points. Odds ratios (OR) and 95% confidence 
interval (CI) were calculated. The residual imbalance of 
adjusting covariates was addressed by a “doubly robust” 
method, incorporating relevant covariates in two regression 
models: a propensity-score model and an outcome regression 
model [16]. The first model was fitted to account for the non-
randomized use of different LMWH dosages. The individual 
propensities for receiving a prophylactic LMWH dose were 
estimated through a logistic regression model, including 
baseline demographic/clinical characteristics and comorbidi-
ties (see Tables 1 and 2). We then added the propensity score 
based on patients’ characteristics as an additional covariate 
into the outcome regression model (Fig. 2 of the Online 
Appendix). This latter model included demographic factors 
(age, gender, body weight), clinical factors (comorbidities, 
chronic use of antiplatelet or oral anticoagulant therapy), 
laboratory findings  (PaO2/FiO2) and in-hospital medications 
for COVID-19. In order to adjust for timing of LMWH ini-
tiation, early administration of LMWH (< 24 h from admis-
sion) was also added as a covariate.
A subgroup analysis was additionally performed to test 
the interaction between earlier administration of LMWH and 
mortality with different doses of LMWH. With the aim to 
keep into account differences in follow-up duration between 
the two study groups, a time-to-event analysis was performed 
for the primary end-point by using the time on LMWH treat-
ment as a time-dependent variable. An estimation of survival 
at 30 days was calculated by the Kaplan–Meier method, with 
differences between different LMWH dosing regimens being 
assessed by log-rank test.
Two sensitivity analyses were conducted. We evaluated 
the primary outcome with different LMWH dosages strati-
fying by the risk of death at hospital presentation using the 
4C Mortality Score; it classifies the risk of death of COVID-
19 patients, based on clinical features on admission, into 
four groups: low, intermediate, high and very high risk 
[17]. Thus, we estimated the association of 4000 IU daily 
dose of enoxaparin vs. > 4000 IU daily dose for the primary 
end-point in the subgroups with low/intermediate and high/
very high risk. Moreover, to test the relationship between 
thrombo-prophylaxis and outcome at the extreme of body 
weight (obesity or underweight), we performed a sensitivity 
analysis in the subgroup of patients in whom a precise body 
weight was identified on the source documents (N = 212). 
We classified the body weight-adjusted enoxaparin dose as 
prophylactic (≤ 70 IU/kg daily) or higher (> 70 IU/kg daily) 
and evaluated the association of the two regimens with the 
primary end-point. A logistic regression analysis was also 
performed in the two sensitivity estimations, as previously 
indicated for the primary assessments. Statistical analyses 
were performed by Stata software, version 16.0.
Results
A total of 287 patients (65.8%) received a prophylactic 
enoxaparin dose (4000 IU daily) and 149 (34.2%) a higher 
enoxaparin dose (> 4000  IU daily). The distribution of 
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baseline characteristics, clinical presentation, comorbidities, 
concomitant treatments and laboratory findings according to 
the enoxaparin dosing regimen is shown in Tables 1 and 2. 
A prophylactic enoxaparin dose was associated with lower 
body weight, reduced prevalence of atrial fibrillation and 
severe ARDS at Emergency Department presentation, as 
well as with higher creatinine values and increased  PaO2/
FiO2 at  baseline. Treatment with remdesivir, lopinavir/
ritonavir, steroids and tocilizumab was more frequent in 
patients receiving the higher enoxaparin dosage. The length 
of in-hospital stay was shorter in patients receiving the pro-
phylactic dose (Table 3).
A total of 113 patients (25.9%) had a primary end-point 
event. Crude rates of the study end-points are reported 
in Table 3. Patients on prophylactic enoxaparin dose had 
a comparable incidence of the primary outcome measure 
of all-cause mortality (25.4% vs. 26.9% in those receiving 
the higher dose; p = 0.750). The estimated survival rates at 
30 days among patients on prophylactic vs higher dosing 
regimen were 56.5% (95% CI 45.7–65.9%) and 61.3% (95% 
Table 1  Baseline characteristics 
of patients stratified by 
enoxaparin dose
Data are expressed as n (%) or mean ± standard deviation. ARDS acute respiratory distress syndrome; ED 
emergency department
a Data were missing for obesity in 85 patients (56 in the prophylaxis and 29 in the higher dose group) and 







 Age (years) 71.2 ± 15.6 70.2 ± 13.0 0.175
 Male gender 159 (55.4) 90 (60.4) 0.525
 Body weight (kg) 72.6 ± 13.3 79.3 ± 13.6  < 0.001
Comorbidities
 Arterial hypertension 152 (53.0) 93 (62.4) 0.059
 Diabetes mellitus 66 (23.0) 29 (19.5) 0.397
  Obesitya 34 (14.7) 33 (27.5) 0.004
 Smoking 40 (13.9) 20 (13.4) 0.882
 Heart failure 41 (14.3) 27 (18.1) 0.156
 Atrial fibrillation 22 (7.7) 34 (22.8)  < 0.001
 Peripheral vascular disease 45 (15.7) 20 (12.4) 0.530
 Chronic obstructive pulmonary disease 35 (12.2) 12 (8.1) 0.186
 Chronic renal failure 51 (17.8) 17 (11.4) 0.083
 History of cancer 56 (19.5) 25 (16.8) 0.486
 Chronic liver disease 10 (3.5) 3 (2.0) 0.392
Clinical signs upon presentation
 Systolic blood pressure (mmHg) 129.0 ± 22.2 130.2 ± 22.1 0.591
 Heart rate (bpm) 83.7 ± 14.3 87.3 ± 21.0 0.060
 Body temperature (°C) 37.5 ± 1.1 37.4 ± 1.1 0.425
 Severe ARDS at ED presentation 12 (4.2) 16 (10.7) 0.008
Laboratory findings
 White blood cells (n/mm3) 7757 ± 5652 8460 ± 5245 0.113
 Hemoglobin (g/dL) 12.8 ± 2.0 12.9 ± 2.1 0.601
 Platelets (n/mm3) 213,140 ± 99,410 223,030 ± 97,938 0.383
 C-reactive protein (mg/dL) 23.8 ± 43.6 22.4 ± 38.7 0.336
 Creatinine (mg/dL) 1.3 ± 1.3 1.0 ± 0.6 0.044
 d-Dimer (µg/L)a 4,233 ± 10,227 5,183 ± 13,902 0.616
  PaO2/FiO2 ratio 284.5 ± 100.2 235.4 ± 93.1  < 0.001
Risk of death upon presentation
 4C Mortality Score 0.230
  Low (0–3) 12 (4.2) 2 (1.3)
  Intermediate (4–8) 90 (31.4) 46 (30.9)
  High (9–14) 168 (58.5) 96 (64.4)
  Very high (> 14) 17 (5.9) 5 (3.4)
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CI 49.3–71.3%), respectively (log-rank p = 0.189; Fig. 1). 
Multivariate analysis, also adjusted for the propensity score, 
indicated a similar risk of in-hospital death in the two treat-
ment groups (OR 0.847, 95% CI 0.400–1.792, p = 0.664) 
(Fig. 2). In the overall population, 68.9% of patients received 
enoxaparin < 24 h from Emergency Department presenta-
tion and 80.8% of patients < 48 h. There was no interaction 
between earlier initiation of enoxaparin (< 24 h from admis-
sion) and different doses of enoxaparin in terms of in-hospi-
tal mortality (earlier prophylactic dose 24.8%; earlier higher 
dose 26.3%; late prophylactic dose 27.8%; late higher dose 
25.6%; p for interaction = 0.726).
All secondary outcome measures were associated with 
a significantly lower risk in the prophylactic dose group 
(Fig. 2); in particular, adjusted OR for cardiovascular mor-
tality was 0.165 (95% CI 0.050–0.546, p = 0.003), adjusted 
OR for venous thromboembolism was 0.067 (95% CI 
0.011–0.388, p = 0.003), adjusted OR for new-onset severe 
ARDS was 0.454 (95% CI 0.227–0.910, p = 0.026) and for 
mechanical ventilation was 0.150 (95% CI 0.051–0.441, 
p = 0.010). The incidence of bleeding events was low in 
both groups, without significant differences (major bleed-
ing: 1.5% with the prophylaxis regimen vs. 4.8% with the 
higher dose regimen; clinically relevant non-major bleeding: 
3.1% vs. 4.8%).
Sensitivity analysis showed that, as compared to the 
higher dosing regimen, the use of prophylactic dosage of 
enoxaparin was associated with comparable outcome for 
the primary end-point in patients (N = 286) with high/very 
high risk of death on admission (adjusted OR 1.373, 95% CI 
0.600–3.141, p = 0.452) and an improved outcome in those 
(N = 150) with low/intermediate risk (adjusted OR 0.012, 
95% CI 0.001–0.428, p = 0.015) (p for interaction 0.02) 
(Fig. 3). The analysis according to body weight-adjusted 
enoxaparin dose showed a similar incidence of the primary 
end-point in patients receiving ≤ 70 IU/Kg vs. > 70 IU/Kg 
daily regimen (adjusted OR 0.324, 95% CI 0.093–1.125, 
p = 0.076) (Fig. 3).
Table 2  Medical treatment in patients stratified by enoxaparin dose
Data are expressed as n (%)








 ACE-inhibitors 58 (27.2) 40 (31.0) 0.454
 Sartans 47 (22.2) 35 (27.3) 0.280
 Aspirin 60 (28.0) 40 (32.0) 0.440
  P2Y12 inhibitors 24 (11.4) 17 (13.4) 0.583
 Oral anticoagulants 15 (7.0) 32 (24.8)  < 0.001
COVID-19 treatment
 Hydroxychloroquine 185 (84.9) 117 (9.7) 0.118
 Daunavir 75 (35.5) 48 (39.0) 0.525
 Remdesivir 0 6 (4.9) 0.001
 Lopinavir 33 (15.6) 29 (23.6) 0.069
 Lopinavir/Ritonavir 31 (15.2) 29 (25.2) 0.028
 Azitromicin 76 (35.3) 44 (36.4) 0.852
 Steroids 80 (36.7) 70 (58.8)  < 0.001
 Tocilizumab 19 (9.2) 25 (21.7) 0.002
Table 3  In-hospital outcome 
according to different 
enoxaparin doses
ARDS acute respiratory distress syndrome
a Bleeding was assessed in a subgroup including 65 consecutive patients in the prophylaxis and 21 patients 
in the higher dose group







 All-cause death 73 (25.4) 40 (26.9) 0.750
Secondary end-points
 Cardiovascular death 11 (3.9) 19 (12.8) 0.001
 Venous thromboembolism 3 (1.1) 19 (12.8)  < 0.001
 New-onset severe ARDS 56 (19.5) 74 (49.7)  < 0.001
 Need of mechanical ventilation 15 (5.2) 38 (25.5)  < 0.001
 Major  bleedinga 1 (1.5) 1 (4.8) 0.431
 Clinically relevant non-major  bleedinga 2 (3.1) 1 (4.8) 0.999
 In-hospital length of stay (days)b 13 (8–18) 17 (11–25)  < 0.001
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Discussion
In this analysis, involving a multicenter cohort of patients 
admitted for COVID-19, the use of enoxaparin at prophy-
lactic doses, as compared with higher doses, was associated 
with similar in-hospital mortality.
COVID-19 is a complex disease with both a primary 
involvement of the respiratory system and a pro-coagula-
tive status [2, 3, 12]. As a matter of fact, autoptic studies 
on COVID-19 cadavers showed both micro-vascular lung 
thrombosis and macrovascular systemic or pulmonary 
thrombosis, regardless of antithrombotic treatment, type of 
anticoagulant therapy, and timing of disease course [4–6]; 
this suggests a pivotal role of coagulative patterns in the 
disease process. The indication from the World Health 
Organization on the use of prophylactic LMWH doses in 
patients with COVID-19 [11] was essentially based on 
preliminary evidence showing a benefit compared to no 
thrombo-prophylaxis, mainly in subgroups at higher risk [8, 
9]; such recommendation was consistent with pre-existing 
guidelines for thrombo-prophylaxis in high-risk acutely ill 
Fig. 1  Kaplan–Meier estimates of 30-day survival stratified by differ-
ent doses of enoxaparin
Fig. 2  Adjusted ORs for the 
study end-points with prophy-
lactic vs. higher enoxaparin 
dose. ARDS acute respiratory 
distress syndrome, CI confi-
dence interval, OR Odds ratio
Fig. 3  Adjusted ORs for the pri-
mary end-point with: 4000 IU 
vs. > 4000 IU enoxaparin daily 
dose in the subgroups with 
low/intermediate and high/
very high risk according to the 
4C Mortality Score; ≤ 70 IU/
Kg vs. > 70 IU/Kg enoxaparin 
daily regimen. CI Confidence 
interval; OR Odds ratio
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patients [18–20]. However, small observational studies dem-
onstrated rates > 20% of thrombotic complications among 
critically ill patients with COVID-19, despite standard 
thrombo-prophylaxis [3, 9, 21]. Although flawed by the use 
of heterogeneous agents and variable dosages, these reports 
generated a source of concern and encouraged the use of 
intermediate or full-dose anticoagulation in this setting. Two 
recent investigations from the same study group showed a 
survival benefit of full-dose anticoagulation in patients hos-
pitalized for COVID-19 [7], especially when initiated > 48 h 
from admission [22]; these results are challenging to inter-
pret and export in clinical practice, given the mixing of 
oral, subcutaneous or intravenous agents and the absence of 
specific information on treatment indication and dosages. 
Thus, given the lack of direct comparisons between prophy-
lactic and higher regimens, the optimal dosage of LMWH 
for preventing thrombotic events in patients with COVID-19 
is uncertain and is a matter of active debate.
We explored this issue in a consecutive cohort of patients 
hospitalized in three Italian Hospitals, in whom a spe-
cific comparison of two dosages of enoxaparin (4000 IU 
vs. > 4000 IU daily) was performed. Notably, regardless 
of the dosing strategy, in our series enoxaparin was early 
given (< 48 h from admission in 81% of patients). Patients 
receiving the higher enoxaparin dosing regimen had higher 
body weight, increased frequency of atrial fibrillation, more 
severe hypoxemia upon admission, and received a “more 
aggressive” treatment for COVID-19; the length of stay 
was also longer. On the other hand, patients treated with the 
prophylaxis regimen had a higher prevalence of risk factors 
increasing the COVID-19-related mortality, i.e. older age, 
diabetes mellitus, chronic obstructive pulmonary disease, 
renal failure and cancer [23]. Thus, to reduce residual con-
founding and limit the bias from unbalanced baseline fea-
tures in the study population, we performed a logistic regres-
sion analysis, where the propensity score was also added 
as covariate. Here the use of prophylactic and higher dose 
of enoxaparin resulted in a similar incidence of in-hospital 
mortality, even after adjustment for the timing of drug ini-
tiation. The consistency of results in the sensitivity analysis 
among higher risk patients strengthens the robustness of the 
primary analysis by further minimizing the risk of treatment 
bias, at least in this more critical setting. These findings lead 
support to the recent decision of the United States National 
Institutes of Health to stop the ongoing randomized trial 
on anticoagulants in high-risk patients with COVID-19 for 
futility and potential harm [24]. Notably, in our study, the 
use of prophylactic doses of enoxaparin in patients at low 
or intermediate baseline risk was associated with reduced 
in-hospital death, but this merits further confirmation in a 
larger, specific investigation.
The concomitant reduction of new-onset severe ARDS 
and venous thromboembolism in patients treated with 
prophylaxis regimen supports that both lung microvas-
cular angiopathy and macrovascular venous thrombosis 
have a predominant role in the pathogenesis and natural 
history of COVID-19 [2–6]. Prevention of these throm-
botic phenomena may reduce the need for mechanical 
ventilation and translate into a significant benefit in terms 
of lower cardiovascular death, as observed in the present 
study. According to our results, in the context of patients 
with COVID-19 (i.e., characterized by mounting inflam-
mation, cytokine storm and imbalance of the hemostatic 
system), an approach of full anticoagulation with thera-
peutic doses of LMWH could not be optimal. Notably, 
COVID-19-related lung microvascular angiopathy shares 
similar pathogenetic mechanisms with complement‐medi-
ated thrombotic microangiopathy [5, 25, 26] and here full 
dose anticoagulation yielded unsatisfactory results [25]. 
Various features may explain the reason of why, in the 
absence of indication to therapeutic dosages for an active 
macrovascular thrombosis, dosing regimens of LMWH 
higher than prophylactic in patients with COVID-19 
are associated with a poorer outcome: increased risk of 
heparin-induced thrombocytopenia, leading to further 
enhancement of the pro-thrombotic status; lower “pleio-
tropic” (anti-inflammatory and immunomodulant) effects 
[27]; increased risk of intraparenchymal bleeding and 
hemorrhagic infarctions in the lung, already described 
in COVID-19 pathology findings and possibly underesti-
mated/undiagnosed in the COVID-19 scenario [28]. How-
ever, these hypotheses require specific evaluations in ad 
hoc, mechanistic studies.
We performed an additional sensitivity analysis by com-
paring prophylactic vs. higher body weight-adjusted enoxa-
parin doses (≤ 70 IU/Kg vs. > 70 IU/Kg daily). It confirmed 
no advantage of higher enoxaparin dosages in terms of all-
cause death. Thus, our data support a standard approach 
of 4000 IU enoxaparin daily dose, with a strategy of body 
weight-adjusted dosing regimen (70 IU/Kg daily) being used 
in patients at the extremes of body weight. This approach 
is in agreement with the recommendation of the European 
Society of Cardiology expert consensus on LMWH dosing 
[29], suggesting that fixed prophylactic doses should be uti-
lized in patients with normal weight, overweight and mild 
obesity; LMWH dose should be adjusted for the body weight 
only in patients with underweight or severe obesity. Indeed, 
in patients with COVID-19, a body weight-adjusted dosing 
appears crucial mainly in obese patients, where an additional 
mortality risk and a higher intrinsic risk of thromboembolic 
complications have been described [30, 31].
The present study confirms previous reports indicating a 
low incidence of hemorrhagic complications in patients with 
COVID-19 and reinforces the concept that the thrombotic 
risk rather than bleeding risk is the major concern in this 
setting [7]. In our investigation, the low rates of both major 
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bleeding and clinically relevant non-major bleeding preclude 
any definite conclusion on the risk of hemorrhagic events 
with prophylactic vs. higher enoxaparin doses.
Study limitations
The study has strengths and limitations. A multicenter 
cohort of consecutive patients was included, and individual 
data were accurately collected, with a strict source verifica-
tion for the event adjudication. However, the retrospective 
design and the conduction of the study during a National 
Emergency contributed to the lack of some, although lim-
ited, data, which were not available. Given the observational 
nature, the study should not be used to definitely rule out 
either benefit or harm of different enoxaparin dosing regi-
mens. However, the consistency of the results across mul-
tiple adjustments and analyses is reassuring for the robust-
ness of our findings. Nevertheless, the risk of unmeasured 
confounding remains. Finally, our results specifically refer to 
enoxaparin and whether they are also generalizable to other 
LMWH molecules is unknown.
In conclusion, a prophylactic dose of enoxaparin in 
patients admitted for COVID-19 is associated with similar 
in-hospital mortality compared to higher dosing regimens. 
Our findings are hypothesis-generating and require confir-
mation in a randomized, controlled study.
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